From a translational perspective, the immunomodulatory properties of Dex in ER+ breast cancer suggest its potential for enhancing immunotherapy efficacy, whereas its adverse effects in TNBC highlight the need for combined strategies such as GR antagonists. The gene discussed is NR3C1; the disease is breast carcinoma.